Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
NL-OMON45071Phase 3Recruiting
- Sponsor
- Celgene Corporation
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free survival. Started Dec 2015; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON45071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45071.